Carcinoma Neuroendocrino/tratamiento farmacológico; Receptores de Somatostatina/efectos de los fármacos; Receptores de Somatostatina/fisiología; Animales; Carcinoma Neuroendocrino/diagnóstico; Proliferación Celular/efectos de los fármacos; Dopamina/análogos & derivados; Dopamina/uso terapéutico; Humanos; Octreótido/uso terapéutico; Péptidos Cíclicos/uso terapéutico; Radiofármacos; Transducción de Señal/efectos de los fármacos; Somatostatina/efectos adversos; Somatostatina/análogos & derivados; Somatostatina/uso terapéutico; Serina-Treonina Quinasas TOR/antagonistas & inhibidores

5-HIAA; 5-hydroxyindoleacetic acid; 70-kDa ribosomal protein S6 kinase; ACTH; AIP; AKT8 virus oncogene cellular homolog; Akt; B-cell lymphoma 2; BNCT; Bax; Bcl-2; Bcl-2-associated X; CCK; DAG; DOTA; DR4; DTPA; Dopastatin; GH; GI; GIP; GLP-1; GSK3ß; Grb; Gsp; Gsα subunit protein; HGCT; IGF-1; IP3; IRS-1; JAK; JNK; Janus kinase; LAR; LDL; MAPK; Men1; NET; NHE1; NOS; Na(+)/H(+) exchanger; Neuroendocrine tumor; OGTT; Octreotide; PET; PFS; PI3K; PIP2; PKA/C; PLA/C; POMC; PRL; PTP; Pasireotide; Pituitary; Proliferation; RKIP; Raf; Raf kinase inhibitory protein; Ras; SH2; SH2-containing phosphatase; SHP; SPECT; SSTR; STAT3/5b; Signal transduction; Somatostatin; Somatostatin receptors; Sos; TNFR1; TPE; TSH; TTP; UFC; VEGF; Zac1; adrenocorticotropic hormone; aryl hydrocarbon receptor interacting protein; boron neutron capture therapy; c-Jun NH(2)-terminal kinase; cAMP/cGMP; cholecystokinin; cyclic adenosine/guanosine monophosphate; death receptor 4; diacylglycerol; diethylenetriaminepentaacetic acid; gastrointestinal; glucagon-like peptide 1; glucose-dependent insulinotropic polypeptide; glycogen synthase kinase 3ß; growth factor receptor bound protein; growth hormone; hyperglycemic clamp test; inositol 1,4,5-trisphosphate; insulin receptor substrate 1; insulin-like growth factor 1; long-acting release (or repeatable); low-density lipoprotein; mTOR; mammalian (or mechanistic) target of rapamycin; mitogen-activated protein kinase; multiple endocrine neoplasia 1; neuroendocrine tumors; nitric oxide synthase (endothelial/neuronal); oral glucose tolerance test; p70/S6K; phosphatidylinositol 3-kinase; phosphatidylinositol 4,5-bisphosphate; phospholipase A/C; positron emission tomography; pro-opiomelanocortin; progression-free survival; prolactin; protein kinase A/C; protein tyrosine phosphatase; rapidly accelerated fibrosarcoma; rat sarcoma; rous sarcoma oncogene cellular homolog; signal transducer and activator of transcription 3/5b; single photon emission computed tomography; somatostatin receptor; son of sevenless; src; src homology 2; tetraazacyclododecanetetraacetic acid; thyroid-stimulating hormone; time to tumor progression; transient permeability enhancer; tumor necrosis factor receptor 1; urinary free cortisol; vascular endothelial growth factor; zinc finger protein that induces apoptosis and cell cycle arrest